Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.60 |
| ▸ | CSF1R | P07333 | 3/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.60 |
| ▸ | KIT | P10721 | 3/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.60 |
| ▸ | LCK | P06239 | 3/20 | 0.51 |
| ▸ | PLK4 | O00444 | 2/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.51 |
| ▸ | PAK4 | O96013 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | RET | P07949 | 2/20 | 0.51 |
| ▸ | MET | P08581 | 2/20 | 0.51 |
| ▸ | FLT1 | P17948 | 2/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.51 |
| ▸ | TYK2 | P29597 | 2/20 | 0.51 |
| ▸ | AXL | P30530 | 2/20 | 0.51 |
| ▸ | FLT4 | P35916 | 2/20 | 0.51 |
| ▸ | BLK | P51451 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5196907 | 1.00 | KDR (0.60) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL27673320 | 0.85 | KDR (0.58) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL5196911 | 0.85 | KDR (0.58) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL5250140 | 0.83 | KDR (0.72) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL5206495 | 0.80 | KDR (0.73) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL5206486 | 0.80 | KDR (0.73) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL28567575 | 0.80 | CSF1R (0.81) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL28567573 | 0.80 | CSF1R (0.81) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL6184599 | 0.79 | KDR (0.57) | KDRFGFR1CSF1RPDGFRBKIT | |
| SCHEMBL5252315 | 0.78 | KDR (0.77) | KDRFGFR1CSF1RPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633172-B2 | Cyclodextrin nanotechnology for ophthalmic drug delivery | OCULIS EHF (IS) | 2014-01-21 | — | — | US | claimed |
| US-20050267158-A1 | Polymorphic and amorphous forms of 2,5-dimethyl-2H-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((E)-2 pyridin-2-YL-vinyl)-1H-indazol-6-ylamino]-phenyl}-amide | AGOURON PHARMACEUTICALS, INC. | 2005-12-01 | — | — | US | claimed |
| EP-1814859-A2 | METHODS FOR PREPARING INDAZOLE COMPOUNDS | Pfizer, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| CN-1930148-A | Polymorphic and amorphous forms of 2,5-dimethyl-2h-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indasol-6-ylamino]-phenyl}-amide | PFIZER (US) | 2007-03-14 | — | — | CN | disclosed |
| CN-1930148-A | Polymorphic and amorphous forms of 2,5-dimethyl-2h-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indasol-6-ylamino]-phenyl}-amide | PFIZER (US) | 2007-03-14 | — | — | CN | disclosed |
| EP-1745035-A1 | POLYMORPHIC AND AMORPHOUS FORMS OF 2,5-DIMETHYL-2H-PYRAZOLE-3-CARBOXYLIC ACID-{2-FLUORO-5-¬3-((E)-2-PYRIDIN-2-YLVINYL)-1H-INDAZOL-6-YLAMINO|-PHENYL}-AMIDE | PFIZER INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1745035-A1 | POLYMORPHIC AND AMORPHOUS FORMS OF 2,5-DIMETHYL-2H-PYRAZOLE-3-CARBOXYLIC ACID-{2-FLUORO-5-¬3-((E)-2-PYRIDIN-2-YLVINYL)-1H-INDAZOL-6-YLAMINO|-PHENYL}-AMIDE | PFIZER INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006048761-A2 | METHODS FOR PREPARING INDAZOLE COMPOUNDS | PFIZER INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20050267158-A1 | Polymorphic and amorphous forms of 2,5-dimethyl-2H-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((E)-2 pyridin-2-YL-vinyl)-1H-indazol-6-ylamino]-phenyl}-amide | AGOURON PHARMACEUTICALS, INC. | 2005-12-01 | — | — | US | disclosed |
| US-20050267158-A1 | Polymorphic and amorphous forms of 2,5-dimethyl-2H-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((E)-2 pyridin-2-YL-vinyl)-1H-indazol-6-ylamino]-phenyl}-amide | AGOURON PHARMACEUTICALS, INC. | 2005-12-01 | — | — | US | disclosed |
| US-20050267158-A1 | Polymorphic and amorphous forms of 2,5-dimethyl-2H-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((E)-2 pyridin-2-YL-vinyl)-1H-indazol-6-ylamino]-phenyl}-amide | AGOURON PHARMACEUTICALS, INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005090331-A1 | POLYMORPHIC AND AMORPHOUS FORMS OF 2,5-DIMETHYL-2H-PYRAZOLE-3-CARBOXYLIC ACID {2-FLUORO-5-[3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDASOL-6-YLAMINO]-PHENYL}-AMIDE | PFIZER INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090331-A1 | POLYMORPHIC AND AMORPHOUS FORMS OF 2,5-DIMETHYL-2H-PYRAZOLE-3-CARBOXYLIC ACID {2-FLUORO-5-[3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDASOL-6-YLAMINO]-PHENYL}-AMIDE | PFIZER INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090331-A1 | POLYMORPHIC AND AMORPHOUS FORMS OF 2,5-DIMETHYL-2H-PYRAZOLE-3-CARBOXYLIC ACID {2-FLUORO-5-[3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDASOL-6-YLAMINO]-PHENYL}-AMIDE | PFIZER INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267158-A1 | Polymorphic and amorphous forms of 2,5-dimethyl-2H-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((E)-2 pyridin-2-YL-vinyl)-1H-indazol-6-ylamino]-phenyl}-amide | KDR, FLT4, FLT1 | KDR 1/4885FGFR1 6/4885CSF1R 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.